Page last updated: 2024-11-07

vanillactic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

vanillactic acid: metabolite of catecholamines [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID160637
CHEMBL ID1765649
CHEBI ID88526
SCHEMBL ID2454609
MeSH IDM0044854

Synonyms (33)

Synonym
vanillactic acid
vanillactate
3-methoxy-4-hydroxyphenyllactic acid
alpha,4-dihydroxy-3-methoxybenzenepropanoic acid
vanillylactic acid
2475-56-1
3-(4-hydroxy-3-methoxyphenyl)lactic acid
2-hydroxy-3-(4-hydroxy-3-methoxyphenyl)propanoic acid
CHEMBL1765649
chebi:88526 ,
SCHEMBL2454609
AKOS030242148
4-hydroxy-3-methoxyphenyllactic acid
beta-(4-hydroxy-3-methoxyphenyl)lactic acid
3-(4-hydroxy-3-methoxyphenyl)-lactate
b-(4-hydroxy-3-methoxyphenyl)lactate
3-(4-hydroxy-3-methoxyphenyl)-lactic acid
b-(4-hydroxy-3-methoxyphenyl)lactic acid
3-(3-methoxy-4-hydroxyphenyl)lactate
beta-(4-hydroxy-3-methoxyphenyl)lactate
3-(4-hydroxy-3-methoxyphenyl)lactate
FT-0701317
Q27160414
benzenepropanoic acid, alpha,4-dihydroxy-3-methoxy-
2-hydroxy-3-(4-hydroxy-3-methoxyphenyl)propanoicacid
CAA47556
dl-vanillactic acid lithium salt hydrate
DTXSID40862962
EN300-1452157
mfcd00055232
SY339402
2-hydroxy-3-guaiacylpropanoic acid
alpha,4-dihydroxy-3-methoxy-benzenepropanoic acid;3-(4-hydroxy-3-methoxyphenyl)-lactic acid

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Although not statistically significant, the VMA excretion was also noted to be moderately elevated; however, it is recognized that the present study was unable to establish a highly significant dose-response relationship between lead exposure and HVA excretion, as has been reported earlier in lead-poisoned children."( Neurochemical effect of lead exposure: a study on catecholamine metabolism.
Chia, KS; Koh, D; Ong, CN; Saijoh, K, 1989
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
2-oxo monocarboxylic acidAny monocarboxylic acid having a 2-oxo substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Neurotransmitter disorders819

Bioassays (1)

Assay IDTitleYearJournalArticle
AID592088Antihemorrhagic activity in ddY mouse assessed as inhibition of Protobothrops flavoviridis venom-induced hemorrhage incubated with compound for 10 mins measured after 24 hrs2011Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7
Contribution of cinnamic acid analogues in rosmarinic acid to inhibition of snake venom induced hemorrhage.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (55.56)18.7374
1990's3 (16.67)18.2507
2000's2 (11.11)29.6817
2010's3 (16.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.10

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.10 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index4.46 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.10)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies2 (10.53%)4.05%
Observational0 (0.00%)0.25%
Other17 (89.47%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]